Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions
- PMID: 11455223
- DOI: 10.1159/000055093
Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions
Abstract
Background: Premedication with dexamethasone, ranitidine and clemastine is mandatory for patients receiving paclitaxel to avoid hypersensitivity reactions. The proposed dexamethasone dose is 20 mg orally 12 and 6 h prior to paclitaxel infusion. With this premedication severe hypersensitivity reactions are reduced to 1-2% of the treated patients. Besides this oral schedule a single dose of dexamethasone, 40 mg given i.v., just prior to paclitaxel has been shown to be equally effective. In an attempt to reduce steroid-induced side effects, especially for patients receiving weekly paclitaxel protocols, we reduced the dexamethasone dose.
Patients and methods: A total of 132 patients were treated on an outpatient basis with paclitaxel-containing protocols. Paclitaxel was given in doses of 135-175 mg/m(2) once every 3 weeks in 76 patients and/or with 100 mg/m(2) weekly in 70 patients. Dexamethasone premedication was given in a single dose (40, 20, 10 mg) as an infusion directly before paclitaxel.
Results: 0/46 patients receiving 40 mg dexamethasone premedication in 235 cycles and 0/48 patients receiving 20 mg dexamethasone premedication in 186 cycles experienced a severe hypersensitivity reaction. 1/52 patients receiving 10 mg dexamethasone in 480 applications developed a severe hypersensitivity reaction with bronchospasm, hypotension and supraventricular tachycardia shortly after her first paclitaxel infusion started.
Conclusion: No increase of severe hypersensitivity reactions is seen when dexamethasone premedication is reduced to doses of 20 or even 10 mg prior to paclitaxel infusion.
Copyright 2001 S. Karger GmbH, Freiburg
Similar articles
-
The added value of H2 antagonists in premedication regimens during paclitaxel treatment.Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.
-
Premedication strategy for weekly paclitaxel.Cancer Invest. 2002;20(5-6):666-72. doi: 10.1081/cnv-120003535. Cancer Invest. 2002. PMID: 12197222
-
Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.Support Care Cancer. 2018 Jul;26(7):2471-2477. doi: 10.1007/s00520-018-4087-3. Epub 2018 Feb 12. Support Care Cancer. 2018. PMID: 29435713
-
Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?J Oncol Pharm Pract. 2012 Jun;18(2):250-6. doi: 10.1177/1078155211409473. Epub 2011 Aug 1. J Oncol Pharm Pract. 2012. PMID: 21807762 Review.
-
Prophylaxis for paclitaxel hypersensitivity reactions.Ann Pharmacother. 2001 Sep;35(9):1114-7. doi: 10.1345/aph.10287. Ann Pharmacother. 2001. PMID: 11573863 Review.
Cited by
-
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.Support Care Cancer. 2019 Mar;27(3):927-931. doi: 10.1007/s00520-018-4381-0. Epub 2018 Aug 1. Support Care Cancer. 2019. PMID: 30069696 Clinical Trial.
-
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x. Epub 2014 Dec 18. Support Care Cancer. 2015. PMID: 25519756 Free PMC article.
-
Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.Oncotarget. 2017 Mar 21;8(12):19236-19243. doi: 10.18632/oncotarget.13705. Oncotarget. 2017. PMID: 27911278 Free PMC article.
-
Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.Medicine (Baltimore). 2020 Oct 23;99(43):e22814. doi: 10.1097/MD.0000000000022814. Medicine (Baltimore). 2020. PMID: 33120804 Free PMC article.
-
The added value of H2 antagonists in premedication regimens during paclitaxel treatment.Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical